Now is not the time for complacency when it comes to cyber security, warns the National Cyber Security Centre (NCSC) .
Cyber-security is part of Russia’s military doctrine, and whilst the UK has remained relatively unscathed to date, the impact of cyber activity against Ukrainian targets are being felt around the world. For example, Russia was behind a recent cyber-attack on a global communications company, which affected wind farms and internet users across Central Europe.
Located in the West of Scotland Science Park, this new facility will produce fresh leukopaks for cell and gene therapy research in the UK and Europe
The Cambridge & South Cambs Committee of the Cambridgeshire Chambers of Commerce is running a series of events to tackle the ongoing challenges around recruitment for our Cambridge-based and regional firms.
Starting this week, Thursday 20th October, the first event is being fronted by Nikki Scarr and Danielle Grant from Cambridge-based global life science company, Abcam.
Berlin Authority published a case law regarding the DPO requirements and the risk of conflict of interest due to the dual position of DPO.
In this case the person was simultaneously the managing director of two service companies that processed personal data on behalf of the company for which he was acting as also data protection officer. These service companies are also part of the group; they provide customer service and execute orders.
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DEMONSTRATE SIGNIFICANTLY ACCELERATED INSULIN ABSORPTION AND EARLY EXPOSURE COMPARED TO GOLD STANDARD INSULINS NOVOLOG® AND FIASP®
For 2022 only the Oncology Conference and the Precision Medicine Conference will both run in conjunction with each other. Join Bionow, expert speakers and industry colleagues to discuss the current oncology landscape and the future of precision medicine.
DIVERSA is your One Nucleus member expert in drug delivery systems and pharmaceutical technology. DIVERSA is a spin-off of the Health Research Institute of Santiago de Compostela (IDIS) and the Servizo Galego de Saúde (SERGAS) established in January 2022. We have a global vocation to enable innovative therapies get to the clinic and the patients.
In line with its internationalization efforts, DIVERSA has been selected under the ICEX NEXT program on a competitive basis amongst more than 150 Spanish SMEs. There are two main reasons, we have been granted this chance: